Tl Reynolds

SAT0222 BIIB059, a monoclonal antibody targeting BDCA2, shows evidence of biological activity and early clinical proof of concept in subjects with active cutaneous le

B. Werneburg, J. Merola, L. Stevenson, 2017 .